Invivyd, Inc. (IVVD) Q3 2025 Earnings Call Transcript

Invivyd (IVVD) reported Q3 2025 revenues up 11% QoQ and 41% YoY, concurrently announcing a pivotal shift in its strategy after receiving FDA feedback to develop its vaccine alternative antibody, VYD2311, for broad COVID prevention. The company raised approximately $87 million to fund the VYD2311 pivotal clinical program, which is set to initiate by year-end with top-line data anticipated mid-2026, aiming to demonstrate superior safety and efficacy against current mRNA vaccines for a multi-billion dollar market opportunity. Invivyd remains well-capitalized through this milestone, while its existing PEMGARDA commercial franchise continues to expand.

Analysis

Invivyd (IVVD) reported robust Q3 2025 financial results, with revenues increasing 11% quarter-on-quarter and 41% year-over-year, signaling strong commercial momentum. This performance coincides with a pivotal strategic shift, as the company received positive FDA feedback for its next-generation COVID prevention antibody, VYD2311, targeting broad populations. Invivyd successfully raised approximately $87 million in capital, ensuring it is well-funded through the anticipated mid-2026 top-line data readout for VYD2311's pivotal clinical program.

The VYD2311 program, set to initiate by year-end, aims to address perceived limitations of current mRNA vaccines, particularly regarding safety and the lack of modern randomized efficacy data. The Declaration study will assess VYD2311's efficacy and durability, while the LIBERTY study will conduct a head-to-head safety comparison against mRNA vaccines. Management projects "blockbuster potential" for VYD2311, targeting a share of the $3.8 billion U.S. COVID vaccine market.

Invivyd's existing PEMGARDA commercial infrastructure, including over 15,000 contracted GPO sites, provides a scalable foundation for VYD2311's potential launch, with PEMGARDA continuing to be offered. The company also highlighted early-stage discovery efforts in RSV and measles, indicating future pipeline diversification. This comprehensive strategy, coupled with strong financial health, positions Invivyd for significant growth.

Key Decisions for Investors

• Monitor the initiation and progress of VYD2311's pivotal clinical trials, with particular attention to the mid-2026 top-line data, as this represents a critical value inflection point for IVVD.
• Evaluate IVVD's potential market penetration for VYD2311 against the $3.8 billion U.S. COVID vaccine market, considering the competitive landscape and the company's stated safety and efficacy differentiators.
• Assess the sustainability of PEMGARDA's revenue growth and its contribution to overall financial stability, while also watching for updates on early-stage RSV and measles programs for future pipeline diversification.